|Dr. Isa Odidi Ph.D., MBA||Co-Founder, Chairman, CEO & Co-Chief Scientific Officer||364.26k||N/A||1958|
|Dr. Amina Odidi||Pres, COO, Co-Chief Scientist Officer & Director||364.26k||N/A||1960|
|Mr. Greg Powell CPA, CGA||Chief Financial Officer||N/A||N/A||N/A|
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablet; Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; Protonix, a pantoprazole sodium delayed-release capsule to treat gastroesophageal reflux disease; and Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy. In addition, the company offers Pristiq, a desvenlafaxine extended-release tablet to treat depression; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; Ranexa, a ranolazine extended release tablet for chronic angina; and Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.
Intellipharmaceutics International Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.